208 related articles for article (PubMed ID: 16625818)
21. Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice.
Harris HJ; Kotelevtsev Y; Mullins JJ; Seckl JR; Holmes MC
Endocrinology; 2001 Jan; 142(1):114-20. PubMed ID: 11145573
[TBL] [Abstract][Full Text] [Related]
22. Cortisol--cause and cure for metabolic syndrome?
Walker BR
Diabet Med; 2006 Dec; 23(12):1281-8. PubMed ID: 17116176
[TBL] [Abstract][Full Text] [Related]
23. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?
van Raalte DH; Ouwens DM; Diamant M
Eur J Clin Invest; 2009 Feb; 39(2):81-93. PubMed ID: 19200161
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Su X; Vicker N; Potter BV
Prog Med Chem; 2008; 46():29-130. PubMed ID: 18381124
[No Abstract] [Full Text] [Related]
25. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action.
Seckl JR
Curr Opin Pharmacol; 2004 Dec; 4(6):597-602. PubMed ID: 15525550
[TBL] [Abstract][Full Text] [Related]
26. Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Olson S; Aster SD; Brown K; Carbin L; Graham DW; Hermanowski-Vosatka A; LeGrand CB; Mundt SS; Robbins MA; Schaeffer JM; Slossberg LH; Szymonifka MJ; Thieringer R; Wright SD; Balkovec JM
Bioorg Med Chem Lett; 2005 Oct; 15(19):4359-62. PubMed ID: 16039856
[TBL] [Abstract][Full Text] [Related]
27. Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Odermatt A
Expert Opin Ther Pat; 2009 Oct; 19(10):1477-83. PubMed ID: 19780703
[TBL] [Abstract][Full Text] [Related]
28. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
29. Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
Richards S; Sorensen B; Jae HS; Winn M; Chen Y; Wang J; Fung S; Monzon K; Frevert EU; Jacobson P; Sham H; Link JT
Bioorg Med Chem Lett; 2006 Dec; 16(24):6241-5. PubMed ID: 17000111
[TBL] [Abstract][Full Text] [Related]
30. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
[TBL] [Abstract][Full Text] [Related]
31. Nicotine-induced over-exposure to maternal glucocorticoid and activated glucocorticoid metabolism causes hypothalamic-pituitary-adrenal axis-associated neuroendocrine metabolic alterations in fetal rats.
Xu D; Liang G; Yan YE; He WW; Liu YS; Chen LB; Magdalou J; Wang H
Toxicol Lett; 2012 Mar; 209(3):282-90. PubMed ID: 22265867
[TBL] [Abstract][Full Text] [Related]
32. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
33. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
Blum A; Favia AD; Maser E
Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
Yang H; Dou W; Lou J; Leng Y; Shen J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
[TBL] [Abstract][Full Text] [Related]
35. Diet and the role of 11beta-hydroxysteroid dehydrogenase-1 on obesity.
London E; Castonguay TW
J Nutr Biochem; 2009 Jul; 20(7):485-93. PubMed ID: 19443197
[TBL] [Abstract][Full Text] [Related]
36. Influence of sub-chronic selective 11β-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys.
Hamilton BS; Schoelch C; Schuler-Metz A; Krosky P; Lala DS; Claremon DA; McGeehan GM
Eur J Pharmacol; 2016 Oct; 789():68-74. PubMed ID: 27393460
[TBL] [Abstract][Full Text] [Related]
37. Glucocorticoids and the insulin resistance syndrome.
Siminialayi IM; Emem-Chioma PC
Niger J Med; 2004; 13(4):330-5. PubMed ID: 15523856
[TBL] [Abstract][Full Text] [Related]
38. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.
Siu M; Johnson TO; Wang Y; Nair SK; Taylor WD; Cripps SJ; Matthews JJ; Edwards MP; Pauly TA; Ermolieff J; Castro A; Hosea NA; LaPaglia A; Fanjul AN; Vogel JE
Bioorg Med Chem Lett; 2009 Jul; 19(13):3493-7. PubMed ID: 19473839
[TBL] [Abstract][Full Text] [Related]
39. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Hale C; Véniant M; Wang Z; Chen M; McCormick J; Cupples R; Hickman D; Min X; Sudom A; Xu H; Matsumoto G; Fotsch C; St Jean DJ; Wang M
Chem Biol Drug Des; 2008 Jan; 71(1):36-44. PubMed ID: 18069989
[TBL] [Abstract][Full Text] [Related]
40. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
